eGenesis aims to make available safe and reliable Xeno organs, tissues, and cells to patients in need and advance the field of transplantation. It uses gene-editing tools, such as CRISPR, to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date. It develops an initial product for the clinic for kidney transplants, with the longer-term potential of addressing a broader organ recipient population and expanding the applicability of xenotransplantation into other areas such as cell therapy. The company was founded in 2015 and is based in Cambridge, U.K.

Applied StemCell (ASC) is a biotechnology company providing animal and cell line models as tools for drug discovery and diagnostics. Using its TARGATT gene modification technology, the company makes site-specific Knockin mouse, rat and human cell line models fast and efficient for pharmaceutical and academic community.

Somagenics specializes in developing innovative technologies that focus on RNA molecules as therapeutic agents and targets as well as biomarkers. Besides the Real-Seq kit family, the company's detection technology platforms also include miR-ID, a novel circularization-based RT-qPCR method for small RNA detection (specifically isomiRs and isoforms), and res-Q, a method for quantifying fragmented RNA from formaldehyde-fixed, paraffin-embedded histology specimens. SomaGenics's therapeutics platform includes development of targets for its proprietary small short hairpin RNA (sshRNA) in wound healing and anti-viral applications.

ElevateBio creates and operates a portfolio of cell and gene therapy companies to develop, manufacture and commercialize life-transforming medicines. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Myllia Biotechnology is a biotechnology company developing technology that supports the identification of the critical genes and pathways driving certain disease states or impacting the disease phenotype. The company combines CRISPR screening with single-cell RNA sequencing to enable genetic screening for complex phenotypes. Its applications are used in identifying drug targets or elucidating unknown mechanisms of actions of drugs. Myllia Biotechnology, formerly Aelian Biotechnology, was founded in 2018 and is based in Vienna, Austria.

Inscripta develops a gene-editing technology that offers digital genome engineering. It generates low-cost libraries of thousands of designer protein, pathway, or genome variants with trackable mutations and helps researchers to design and track results. The company was founded in 2015 and is based in Boulder, Colorado.